X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs SUN PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD SUN PHARMA LUPIN LTD/
SUN PHARMA
 
P/E (TTM) x 16.6 15.3 108.3% View Chart
P/BV x 3.9 3.6 107.3% View Chart
Dividend Yield % 0.8 0.2 374.7%  

Financials

 LUPIN LTD   SUN PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
SUN PHARMA
Mar-16
LUPIN LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,1271,201 177.1%   
Low Rs1,294706 183.2%   
Sales per share (Unadj.) Rs304.1117.5 258.9%  
Earnings per share (Unadj.) Rs50.419.6 257.2%  
Cash flow per share (Unadj.) Rs60.723.8 254.9%  
Dividends per share (Unadj.) Rs7.501.00 750.0%  
Dividend yield (eoy) %0.40.1 418.1%  
Book value per share (Unadj.) Rs243.8130.5 186.8%  
Shares outstanding (eoy) m450.582,406.60 18.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.68.1 69.3%   
Avg P/E ratio x33.948.7 69.8%  
P/CF ratio (eoy) x28.240.1 70.4%  
Price / Book Value ratio x7.07.3 96.0%  
Dividend payout %14.95.1 291.6%   
Avg Mkt Cap Rs m770,7402,294,813 33.6%   
No. of employees `00016.414.7 110.9%   
Total wages/salary Rs m21,07747,971 43.9%   
Avg. sales/employee Rs Th8,379.619,169.8 43.7%   
Avg. wages/employee Rs Th1,289.03,253.0 39.6%   
Avg. net profit/employee Rs Th1,388.73,197.9 43.4%   
INCOME DATA
Net Sales Rs m137,016282,697 48.5%  
Other income Rs m1,8776,170 30.4%   
Total revenues Rs m138,893288,867 48.1%   
Gross profit Rs m37,53583,239 45.1%  
Depreciation Rs m4,63510,135 45.7%   
Interest Rs m4464,769 9.4%   
Profit before tax Rs m34,33074,505 46.1%   
Minority Interest Rs m-88-11,126 0.8%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m11,5369,349 123.4%   
Profit after tax Rs m22,70747,159 48.1%  
Gross profit margin %27.429.4 93.0%  
Effective tax rate %33.612.5 267.8%   
Net profit margin %16.616.7 99.3%  
BALANCE SHEET DATA
Current assets Rs m97,790308,646 31.7%   
Current liabilities Rs m53,872132,477 40.7%   
Net working cap to sales %32.162.3 51.4%  
Current ratio x1.82.3 77.9%  
Inventory Days Days8583 102.1%  
Debtors Days Days12188 138.1%  
Net fixed assets Rs m86,379133,606 64.7%   
Share capital Rs m9012,407 37.4%   
"Free" reserves Rs m105,735266,909 39.6%   
Net worth Rs m109,844314,042 35.0%   
Long term debt Rs m53,73931,167 172.4%   
Total assets Rs m224,378542,196 41.4%  
Interest coverage x77.916.6 468.9%   
Debt to equity ratio x0.50.1 493.0%  
Sales to assets ratio x0.60.5 117.1%   
Return on assets %10.39.6 107.7%  
Return on equity %20.715.0 137.7%  
Return on capital %21.217.8 119.5%  
Exports to sales %49.114.0 350.6%   
Imports to sales %7.43.1 236.9%   
Exports (fob) Rs m67,24439,572 169.9%   
Imports (cif) Rs m10,1998,882 114.8%   
Fx inflow Rs m71,40542,171 169.3%   
Fx outflow Rs m17,80721,583 82.5%   
Net fx Rs m53,59820,588 260.3%   
CASH FLOW
From Operations Rs m-3,69067,694 -5.5%  
From Investments Rs m-69,434-44,549 155.9%  
From Financial Activity Rs m58,126-19,243 -302.1%  
Net Cashflow Rs m-14,9983,902 -384.4%  

Share Holding

Indian Promoters % 46.6 63.7 73.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 5.1 220.3%  
FIIs % 31.9 23.0 138.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 8.3 121.7%  
Shareholders   98,259 133,026 73.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - UNICHEM LAB COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS